Basem Hamid MD PA
Basem Hamid MD PA was paid $29K by Medicaid between Feb 2019 and Nov 2024, across 16 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 69% of everything it billed.
HOUSTON, TX 77089
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 1,085 | $0.00 | |
| 2020 | 916 | $6K | |
| 2021 | 775 | $8K | |
| 2022 | 532 | $1K | |
| 2023 | 282 | $59.60 | |
| 2024incomplete | 434 | $14K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 69% | 1,744 | 1,651 | $20K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 18% | 1,784 | 1,689 | $5K |
| G3002 | Chronic pain management and treatment, monthly bundle including, diagnosis; assessment and monitoring; administration of a validated pain rating scale or tool; the development, implementation, revision, and/or maintenance of a person-centered care plan that includes strengths, goals, clinical needs, and desired outcomes; overall treatment management; facilitation and coordination of any necessary behavioral health treatment; medication management; pain and health literacy counseling; any necessary chronic pain related crisis care; and ongoing communication and care coordination between relevant practitioners furnishing care, e.g. physical therapy and occupational therapy, complementary and integrative approaches, and community-based care, as appropriate. required initial face-to-face visit at least 30 minutes provided by a physician or other qualified health professional; first 30 minutes personally provided by physician or other qualified health care professional, per calendar month. (when using g3002, 30 minutes must be met or exceeded.) | 7.5% | 57 | 53 | $2K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.0% | 30 | 28 | $882.75 |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 1.9% | 15 | 13 | $550.50 |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | <1% | 50 | 49 | $59.60 |
| G0396 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes | <1% | 92 | 92 | $35.63 |
| G9577 | Patients prescribed opiates for longer than six weeks | 0% | 28 | 28 | $0.00 |
| G9561 | Patients prescribed opiates for longer than six weeks | 0% | 28 | 28 | $0.00 |
| G9584 | Patient evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient interviewed at least once during opioid therapy | 0% | 28 | 28 | $0.00 |
| G9578 | Documentation of signed opioid treatment agreement at least once during opioid therapy | 0% | 28 | 28 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 28 | 28 | $0.00 |
4 more codes
| G8730 | Pain assessment documented as positive using a standardized tool and a follow-up plan is documented | 0% | 28 | $0.00 |
| G9562 | Patients who had a follow-up evaluation conducted at least every three months during opioid therapy | 0% | 28 | $0.00 |
| 4004F | 0% | 28 | $0.00 | |
| G9583 | Patients prescribed opiates for longer than six weeks | 0% | 28 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.